Tilray Medical, a division of Tilray Brands, Inc., announced on January 6 that its German subsidiary, Tilray Deutschland GmbH, has secured a tender to supply Luxembourg with its cannabis flower. 

“We are honored to have been selected again to supply medical cannabis to Luxembourg,” said Denise Faltischek, CSO at Tilray and Head of International at Tilray Brands, in a company press release. “This is a testament to the unwavering dedication of our team in providing patients around the world with high-quality medical cannabis products.”

Luxembourg’s Ministry of Health and Social Security has authorized qualified health professionals to prescribe medical cannabis as a treatment option since February 2019. In a post on its website, the agency says that as of January 1, 2025, THC-rich flowering tops will no longer be available, but patients will still have access to CBD-rich cannabis flower and “balanced” THC and CBD flower, along with cannabis oil. 

Access to these products has been increasing since the program was introduced. There were 18 bottles of cannabis oil prescribed in 2022, 2,043 bottles in 2023, and 2,850 since January 2024, which has also contributed to the adjustment of the program. The population of Luxemburg is around 675,000 people. 

In October 2024, the city released tenders for cannabis oil (“THC dominant”, “CBD dominant” and “THC/CBD balanced”) and medicinal cannabis in the form of dried flowering tops (“CBD dominant” and “THC/CBD balanced”).

In November 2024, Tilray Medical launched its first commercial-grown medical cannabis flowers from its Aphria RX GmbH facility in Germany. 

Tilray received the first cannabis cultivation licence issued under Germany’s new Cannabis Act in July 2024. This licence allows Aphria RX to cultivate and manufacture cannabis for medical purposes in Germany.

The cannabis company, which operates in Canada, the United States, Europe, Australia, and Latin America, was the first to receive a cannabis production licence in the country. Canadian cannabis company Aurora and the German company Demecan are also now licensed for production in the country. 

In February 2024, Germany passed the German Medical Cannabis Act, expanding the country’s medical cannabis laws.

Aphria RX has been present in the medical cannabis space in Germany since March 2019, when the company was awarded a licence for the cultivation of medical cannabis in Germany from the German Federal Institute for Drugs and Medical Devices (the “BfArM”).

Any company that wishes to cultivate, produce, trade, import, export, dispense, sell, otherwise place on the market, obtain or acquire cannabis for medicinal purposes or cannabis for medical-scientific purposes in Germany requires a permit from the German Federal Institute for Drugs and Medical Devices.

Tilray’s Q2 financial results are expected January 10. Tilray Brands, Inc. brought in $200 million in net revenue and gross profit of $59.7 million in the first quarter of 2025 but still saw a net loss of $34.7 million (all figures in US dollars).

Related Articles

Tilray’s Aphria RX facility launches its first German-grown cannabis

November 15, 2024

Mother Labs to bring branded cannabis to German market

October 2, 2024

New retail cannabis project in Germany could be good news for Canadian cannabis exporters

December 13, 2024